Showing results (11-20 of 23) with videos related to
Sort By:
Pageof 3
Clinical Pharmacology in Drug Development|September 25, 2024
Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Pritelivir and Its MetabolitesKatharina Erb-Zohar, Susanne Bonsmann, Jörg Pausch, et al.Antiviral Research|July 23, 2018
Novel non-heteroarylpyrimidine (HAP) capsid assembly modifiers have a different mode of action from HAPs in vitroAngelica Corcuera, Katharina Stolle, Stefan Hillmer, et al.Clinical Pharmacology in Drug Development|January 8, 2024
Mass Balance and Metabolite Profile after Single and Multiple Oral Doses of Pritelivir in Healthy SubjectsSusanne Bonsmann, David McCormick, Jörg Pausch, et al.Clinical Pharmacology in Drug Development|March 2, 2023
First-in-Human, Single- and Multiple-Ascending-Dose, Food-Effect, and Absolute Bioavailability Trials to Assess the Pharmacokinetics, Safety, and Tolerability of Pritelivir, a Nonnucleoside Helicase-Primase Inhibitor Against Herpes Simplex Virus in Healthy SubjectsDirk Kropeit, Susanne Bonsmann, Oliver von Richter, et al.Journal of Medicinal Chemistry|October 6, 2022
Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus InfectionsAlexander Birkmann, Susanne Bonsmann, Dirk Kropeit, et al.Antiviral Research|November 9, 2017
Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitisDebra C Quenelle, Alexander Birkmann, Thomas Goldner, et al.Antimicrobial Agents and Chemotherapy|April 23, 2014
Pharmacokinetics-pharmacodynamics of the helicase-primase inhibitor pritelivir following treatment of wild-type or pritelivir-resistant virus infection in a murine herpes simplex virus 1 infection modelSubhajit Biswas, Soumi Sukla, Thomas Goldner, et al.JAMA|December 21, 2016
Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical TrialAnna Wald, Burkhard Timmler, Amalia Magaret, et al.The Journal of Infectious Diseases|April 9, 2016
No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily TherapyPaul T Edlefsen, Alexander Birkmann, Meei-Li Huang, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 29, 2025
Refractory and Resistant Herpes Simplex Virus Mucocutaneous Infections in Immunocompromised Patients: Literature Review and Proposed Definitions for Use in Clinical TrialsRoy F Chemaly, Tali Shafat, Anna Wald, et al.Pageof 3